Dan H. Barouch

Active 1994–2026

306
Papers
56,328
Citations
121
h-index
291
i10-index

Citations

Citations per year for Dan H. Barouch1982: 1 citations1985: 1 citations1990: 2 citations1993: 7 citations1994: 1 citations1995: 2 citations1996: 7 citations1997: 14 citations1998: 74 citations1999: 127 citations2000: 178 citations2001: 170 citations2002: 244 citations2003: 202 citations2004: 217 citations2005: 195 citations2006: 191 citations2007: 162 citations2008: 177 citations2009: 179 citations2010: 182 citations2011: 170 citations2012: 158 citations2013: 202 citations2014: 193 citations2015: 209 citations2016: 258 citations2017: 380 citations2018: 511 citations2019: 1,432 citations2020: 2,065 citations2021: 4,318 citations2022: 3,784 citations2023: 2,007 citations2024: 2,351 citations2025: 1,028 citations2026: 24 citations1983–1984: no citations, so these years are not shown1986–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,506 citing papers, 32.3% of this breakdownChina: 1,987 citing papers, 8.6% of this breakdownUnited Kingdom: 1,637 citing papers, 7.1% of this breakdownGermany: 1,029 citing papers, 4.4% of this breakdownNetherlands: 773 citing papers, 3.3% of this breakdownCanada: 766 citing papers, 3.3% of this breakdownFrance: 725 citing papers, 3.1% of this breakdownItaly: 639 citing papers, 2.8% of this breakdownAustralia: 632 citing papers, 2.7% of this breakdownSwitzerland: 576 citing papers, 2.5% of this breakdownJapan: 432 citing papers, 1.9% of this breakdownIndia: 430 citing papers, 1.8% of this breakdown
0%32.3%Other 26.2%

Fields

  • Medicine54.2%
  • Immunology and Microbiology28.1%
  • Biochemistry, Genetics and Molecular Biology11.9%
  • Pharmacology, Toxicology and Pharmaceutics1.2%
  • Environmental Science0.9%
  • Engineering0.7%
  • Other3%

Topics

  • SARS-CoV-2 and COVID-19 Research12.2%
  • Immunotherapy and Immune Responses7%
  • COVID-19 Clinical Research Studies6.4%
  • HIV Research and Treatment5%
  • Immune Cell Function and Interaction4.8%
  • vaccines and immunoinformatics approaches4.1%
  • Other60.5%

Coauthors

All papers

Open in search
  1. An immunogenic personal neoantigen vaccine for patients with melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dan H. Barouch, Jon C. Aster, Gad Getz, Kai W. Wucherpfennig, Donna Neuberg, Jerome Ritz, Eric S. Lander, Edward F. Fritsch, Nir Hacohen, Catherine J. Wu - Nature 2017 cited by 2,980

  2. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bradley L. Pentelute, Nir Hacohen, Kenneth J. Livak, Sachet A. Shukla, Lars Rønn Olsen, Dan H. Barouch, Kai W. Wucherpfennig, Edward F. Fritsch, Derin B. Keskin, Catherine J. Wu, Patrick A. Ott - Nature Medicine 2021 cited by 518

  3. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 2,601

  4. Correlates of protection against SARS-CoV-2 in rhesus macaques

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2020 cited by 1,238

  5. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2023 cited by 173

  6. Potently neutralizing and protective human antibodies against SARS-CoV-2

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nicole L. Kallewaard, Broc T. McCune, Shamus P. Keeler, Michael J. Holtzman, Dan H. Barouch, Lisa E. Gralinski, Ralph S. Baric, Larissa B. Thackray, Michael Diamond, Robert H. Carnahan, James E. Crowe - Nature 2020 cited by 1,201

  7. Novel approaches for vaccine development

    Authors: , , , , , - Cell 2021 cited by 356

  8. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1

    Authors: , , , , , , , , , , - New England Journal of Medicine 2023 cited by 241

  9. Covid-19 Vaccines — Immunity, Variants, Boosters

    Authors: - New England Journal of Medicine 2022 cited by 468

  10. Animal models for COVID-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ivana Knežević, Philip R. Krause, Jens H. Kuhn, Roger Le Grand, Mark G. Lewis, Wen‐Chun Liu, Pauline Maisonnasse, Anita K. McElroy, Vincent J. Munster, Nadia Oreshkova, Angela L. Rasmussen, Joana Rocha‐Pereira, Barry Rockx, Estefanía Rodríguez, Thomas F. Rogers, Francisco J. Salguero, Michael Schotsaert, Koert J. Stittelaar, Hendrik Jan Thibaut, Chien‐Te K. Tseng, Júlia Vergara‐Alert, Martin Beer, Trevor Brasel, Jasper Fuk‐Woo Chan, Adolfo García‐Sastre, Johan Neyts, Stanley Perlman, Douglas S. Reed, Jüergen A. Richt, Chad J. Roy, Joaquím Segalés, Seshadri S. Vasan, Ana María Henao-Restrepo, Dan H. Barouch - Nature 2020 cited by 880

  11. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

    Authors: , , , , , , , , , , - New England Journal of Medicine 2022 cited by 589

  12. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

    Authors: , , , , , , , , , , , , - Nature 2022 cited by 459

  13. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 229

  14. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charlotte-Paige Rolle, Roberto C. Arduino, Edwin DeJesus, Georgia D. Tomaras, Michael S. Seaman, Bette Korber, Dan H. Barouch - Nature Medicine 2022 cited by 141

  15. Phenotypic Analysis of Antigen-Specific T Lymphocytes

    Authors: , , , , , , , - Science 1996 cited by 3,581

  16. T cell immunity to COVID-19 vaccines

    Authors: , - Science 2022 cited by 215

  17. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Science Immunology 2022 cited by 140

  18. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ralph S. Baric, Stefan O. Mueller, Benjamin Petsch, Dan H. Barouch - Nature 2021 cited by 133

  19. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 cited by 96

  20. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 250

  21. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 1,184

  22. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frances Priddy, Erica Lazarus, Fatima Laher, Sorachai Nitayapan, Punnee Pitisuttithum, Stephan Bart, Thomas Campbell, Robert Feldman, Gregg Lucksinger, Caroline Borremans, Katleen Callewaert, Raphaele Roten, Jerald Sadoff, Lorenz Scheppler, Mo Weijtens, Karin Feddes-de Boer, Daniëlle van Manen, Jessica Vreugdenhil, Roland Zahn, Ludo Lavreys, Steven Nijs, Jeroen Tolboom, Jenny Hendriks, Zelda Euler, Maria Grazia Pau, Hanneke Schuitemaker - The Lancet 2018 cited by 342

  23. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2022 cited by 105

  24. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, David M. Weinreich - New England Journal of Medicine 2021 cited by 480